Merck & Co., Inc. Quarterly Report for Q2 Ended Jun 30, 2023

Summary

Merck & Co., Inc. reported net sales of $15.0 billion for the second quarter of 2023, a 3% increase year-over-year, driven by strong performance in its Oncology and Vaccines segments, particularly Keytruda and Gardasil 9. However, the company recorded a significant net loss of $5.97 billion ($2.35 loss per share) for the quarter, a stark contrast to the net income of $3.94 billion ($1.56 earnings per share) in the prior year period. This loss was largely attributable to a substantial charge related to the acquisition of Prometheus Biosciences, Inc., which impacted research and development expenses. Despite the quarterly loss, the company's financial position remains robust, with significant cash reserves and operational cash flow generation.

Key Highlights

• 1Second quarter 2023 sales reached $15.0 billion, up 3% year-over-year, driven by Keytruda and Gardasil 9.
• 2Reported a net loss of $5.97 billion for Q2 2023, compared to a net income of $3.94 billion in Q2 2022, primarily due to the Prometheus acquisition charge.
• 3Research and Development expenses significantly increased to $13.3 billion in Q2 2023 from $2.8 billion in Q2 2022, largely driven by the Prometheus acquisition.
• 4The oncology franchise, led by Keytruda, showed strong growth with sales up 19% to $6.3 billion in Q2 2023.
• 5Vaccines, particularly Gardasil 9, also demonstrated robust growth with sales up 47% to $2.5 billion in Q2 2023.
• 6The company continues to invest in its pipeline, with significant progress noted for Keytruda in various cancer indications and other new drug candidates.
• 7Cash provided by operating activities was $5.0 billion for the first six months of 2023, though lower than the prior year, indicating continued strong operational cash generation.

Frequently Asked Questions